Hyperfine
HYPR Micro CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Hyperfine en bref
Hyperfine (HYPR) is currently trading at 0,81 € with a market capitalization of 81 M €. The 52-week range spans from 0,74 € to 1,92 €; the current price is 57.7% below the yearly high. Year-over-year revenue growth stands at +82.6%.
💰 Dividende
Hyperfine currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
3 analystes évaluent Hyperfine (HYPR) au consensus : None. L'objectif de cours moyen est de 1,88 €, soit un potentiel de +131.53% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 1,73 € à 2,17 €.
Hyperfine : la thèse d'investissement en détail
Hyperfine (HYPR) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 82.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 131.53% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 82.6% sur un an
- Marge brute élevée de 51.2% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 38.91)
- –Actuellement non rentable
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Hyperfine?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news